Inhaled therapy aims to halt lung decline in rare genetic disease
Disease control
Recruiting now
This study tests whether daily inhaled AAT (a protein) can slow lung function loss in people with Alpha-1 antitrypsin deficiency, a genetic condition that causes emphysema. About 220 adults with moderate to severe lung disease will receive either the drug or a placebo for 2 years…
Phase: PHASE3 • Sponsor: Kamada, Ltd. • Aim: Disease control
Last updated May 17, 2026 15:00 UTC